Cannabis in Gastroenterology: Watch Your Head! A Review of Use in Inflammatory Bowel Disease …

  • 1.

    Storr MA, Yüce B, Andrews CN, Sharkey KA. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil. 2008;20(8):857–68. https://doi.org/10.1111/j.1365-2982.2008.01175.x.

    CAS
    Article
    PubMed

    Google Scholar

  • 2.

    • Sharkey KA, Wiley JW. The role of the endocannabinoid system in the brain-gut axis. Gastroenterology. 2016;151(2):252–66. https://doi.org/10.1053/j.gastro.2016.04.015 This is an excellent comprehensive review on how the endocannabinoid system affects brain-gut function.

    CAS
    Article
    PubMed
    PubMed Central

    Google Scholar

  • 3.

    Marinol Monograph. doi:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf. Accessed 8 June 2020.

  • 4.

    Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107(8):e1–e12. https://doi.org/10.2105/AJPH.2017.303818.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • 5.

    Overview | Cannabis-based medicinal products | Guidance | NICE. doi:https://www.nice.org.uk/guidance/ng144. Accessed 8 June 2020.

  • 6.

    Andrews CN, Devlin SM, Le Foll B, Fischer B, Tse F, Storr M, et al. Canadian Association of Gastroenterology Position Statement: use of cannabis in gastroenterological and hepatic disorders. J Can Assoc Gastroenterol. 2019;2(1):37–43. https://doi.org/10.1093/jcag/gwy064.

    Article
    PubMed

    Google Scholar

  • 7.

    Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005;129(2):437–53. https://doi.org/10.1016/j.gastro.2005.05.026.

    Article
    PubMed

    Google Scholar

  • 8.

    Picardo S, Kaplan GG, Sharkey KA, Seow CH. Insights into the role of cannabis in the management of inflammatory bowel disease. Ther Adv Gastroenterol. 2019;12:1756284819870977. https://doi.org/10.1177/1756284819870977.

    CAS
    Article

    Google Scholar

  • 9.

    Couch DG, Maudslay H, Doleman B, Lund JN, O’Sullivan SE. The use of cannabinoids in colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2018;24(4):680–97. https://doi.org/10.1093/ibd/izy014.

    Article
    PubMed

    Google Scholar

  • 10.

    Alhouayek M, Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med. 2012;18(10):615–25. https://doi.org/10.1016/j.molmed.2012.07.009.

    CAS
    Article
    PubMed

    Google Scholar

  • 11.

    Strisciuglio C, Bellini G, Miele E, Martinelli M, Cenni S, Tortora C, et al. Cannabinoid receptor 2 functional variant contributes to the risk for pediatric inflammatory bowel disease. J Clin Gastroenterol. 2018;52(5):e37–43. https://doi.org/10.1097/MCG.0000000000000755.

    CAS
    Article
    PubMed

    Google Scholar

  • 12.

    Storr M, Emmerdinger D, Diegelmann J, Pfennig S, Ochsenkühn T, Göke B, et al. The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn’s disease. PLoS One. 2010;5(2):e9453. https://doi.org/10.1371/journal.pone.0009453.

    CAS
    Article
    PubMed
    PubMed Central

    Google Scholar

  • 13.

    Storr M, Emmerdinger D, Diegelmann J, Yüce B, Pfennig S, Ochsenkühn T, et al. The role of fatty acid hydrolase gene variants in inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29(5):542–51. https://doi.org/10.1111/j.1365-2036.2008.03910.x.

    CAS
    Article
    PubMed

    Google Scholar

  • 14.

    Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–9. https://doi.org/10.1016/j.drugalcdep.2015.08.035.

    Article
    PubMed

    Google Scholar

  • 15.

    Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20(3):472–80. https://doi.org/10.1097/01.MIB.0000440982.79036.d6.

    Article
    PubMed

    Google Scholar

  • 16.

    Phatak UP, Rojas-Velasquez D, Porto A, Pashankar DS. Prevalence and patterns of marijuana use in young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64(2):261–4. https://doi.org/10.1097/MPG.0000000000001474.

    Article
    PubMed

    Google Scholar

  • 17.

    Hoffenberg EJ, McWilliams S, Mikulich-Gilbertson S, Murphy B, Hoffenberg A, Hopfer CJ. Cannabis oil use by adolescents and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2019;68(3):348–52. https://doi.org/10.1097/MPG.0000000000002189.

    Article
    PubMed

    Google Scholar

  • 18.

    Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(13):2809–14. https://doi.org/10.1097/01.MIB.0000435851.94391.37.

    Article
    PubMed

    Google Scholar

  • 19.

    Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23(10):891–6. https://doi.org/10.1097/meg.0b013e328349bb4c.

    Article
    PubMed

    Google Scholar

  • 20.

    Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13(8):455–8.

    PubMed

    Google Scholar

  • 21.

    Mbachi C, Attar B, Wang Y, Paintsil I, Mba B, Fugar S, et al. Association between cannabis use and complications related to Crohn’s disease: a retrospective cohort study. Dig Dis Sci. 2019;64(10):2939–44. https://doi.org/10.1007/s10620-019-05556-z.

    Article
    PubMed

    Google Scholar

  • 22.

    Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Lish I, Konikoff FM, Ringel Y. Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol. 2019;31(11):1376–81. https://doi.org/10.1097/MEG.0000000000001565.

    Article
    PubMed

    Google Scholar

  • 23.

    • Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11(10):1276–80.e1. https://doi.org/10.1016/j.cgh.2013.04.034 This is the first randomized double-blinded placebo-controlled clinical trial of THC in Crohn’s disease.

    CAS
    Article
    PubMed

    Google Scholar

  • 24.

    Naftali T, Mechulam R, Marii A, Gabay G, Stein A, Bronshtain M, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a randomized controlled trial. Dig Dis Sci. 2017;62(6):1615–20. https://doi.org/10.1007/s10620-017-4540-z.

    CAS
    Article

    Google Scholar

  • 25.

    Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of Crohn’s disease. Cochrane Database Syst Rev. 2018;11:CD012853. https://doi.org/10.1002/14651858.CD012853.pub2.

    Article
    PubMed

    Google Scholar

  • 26.

    Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24(4):714–24. https://doi.org/10.1093/ibd/izy002.

    Article

    Google Scholar

  • 27.

    Naftali T, Schlieder LBL, Benjaminov FS, Lish I, Konikoff FM. Sa1744-cannabis induces clinical and endoscopic improvement in moderately active ulcerative colitis. Gastroenterology. 2018;154(6):S-378. https://doi.org/10.1016/s0016-5085(18)31568-3.

    Article

    Google Scholar

  • 28.

    Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of ulcerative colitis. Cochrane Database Syst Rev. 2018;11:CD012954. https://doi.org/10.1002/14651858.CD012954.pub2.

    Article
    PubMed

    Google Scholar

  • 29.

    Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73. https://doi.org/10.1001/jama.2015.6358.

    CAS
    Article
    PubMed

    Google Scholar

  • 30.

    de Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Goor H, Pain, et al. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol. 2017;15(7):1079–86.e4. https://doi.org/10.1016/j.cgh.2016.09.147.

    CAS
    Article
    PubMed

    Google Scholar

  • 31.

    Camilleri M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motil. 2018;30(9):e13370. https://doi.org/10.1111/nmo.13370.

    CAS
    Article
    PubMed
    PubMed Central

    Google Scholar

  • 32.

    Klooker TK, Leliefeld KEM, Van Den Wijngaard RM, Boeckxstaens GEE. The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol Motil. 2011;23(1):30–5, e2. https://doi.org/10.1111/j.1365-2982.2010.01587.x.

  • 33.

    Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141(5):1638–47.e1–7. https://doi.org/10.1053/j.gastro.2011.07.036.

    CAS
    Article
    PubMed
    PubMed Central

    Google Scholar

  • 34.

    Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M, Burton D, et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 2012;24(4):358–e169. https://doi.org/10.1111/j.1365-2982.2011.01874.x.

    CAS
    Article
    PubMed
    PubMed Central

    Google Scholar

  • 35.

    Dothel G, Chang L, Shih W, Barbaro MR, Cremon C, Stanghellini V, et al. μ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol Motil. 2019;31(11):e13688. https://doi.org/10.1111/nmo.13688.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • 36.

    Olorinab (APD371) – Arena Pharmaceuticals.

  • 37.

    Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2006;18(9):831–8. https://doi.org/10.1111/j.1365-2982.2006.00834.x.

    CAS
    Article
    PubMed

    Google Scholar

  • 38.

    Jehangir A, Parkman HP. Cannabinoid use in patients with gastroparesis and related disorders: prevalence and benefit. Am J Gastroenterol. 2019;114(6):945–53. https://doi.org/10.14309/ajg.0000000000000181.

    Article
    PubMed

    Google Scholar

  • 39.

    Barbash B, Mehta D, Siddiqui MT, Chawla L, Dworkin B. Impact of cannabinoids on symptoms of refractory gastroparesis: a single-center experience. Cureus. 2019;11(12):e6430. https://doi.org/10.7759/cureus.6430.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • 40.

    Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53(11):1566–70. https://doi.org/10.1136/gut.2003.036350.

    CAS
    Article
    PubMed
    PubMed Central

    Google Scholar

  • 41.

    Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92. https://doi.org/10.1053/j.gastro.2016.02.011.

    Article
    PubMed

    Google Scholar

  • 42.

    Venkatesan T, Levinthal DJ, Li BUK, Tarbell SE, Adams KA, Issenman RM, et al. Role of chronic cannabis use: cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome. Neurogastroenterol Motil. 2019;31(Suppl 2):e13606. https://doi.org/10.1111/nmo.13606.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • 43.

    Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol. 2014;722:134–46. https://doi.org/10.1016/j.ejphar.2013.09.068.

    CAS
    Article
    PubMed

    Google Scholar

  • 44.

    Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology. 2004;145(12):5431–8. https://doi.org/10.1210/en.2004-0638.

    CAS
    Article
    PubMed

    Google Scholar

  • 45.

    Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience. 2007;145(1):323–34. https://doi.org/10.1016/j.neuroscience.2006.11.012.

    CAS
    Article
    PubMed

    Google Scholar

  • 46.

    Richards JR. Cannabinoid hyperemesis syndrome: a disorder of the HPA axis and sympathetic nervous system? Med Hypotheses. 2017;103:90–5. https://doi.org/10.1016/j.mehy.2017.04.018.

    CAS
    Article
    PubMed

    Google Scholar

  • 47.

    Zhang S-C, Wang W-L, Su P-J, Jiang K-L, Yuan Z-W. Decreased enteric fatty acid amide hydrolase activity is associated with colonic inertia in slow transit constipation. J Gastroenterol Hepatol. 2014;29(2):276–83. https://doi.org/10.1111/jgh.12346.

    CAS
    Article
    PubMed

    Google Scholar

  • 48.

    Rudd JA, Nalivaiko E, Matsuki N, Wan C, Andrews PL. The involvement of TRPV1 in emesis and anti-emesis. Temperature (Austin). 2015;2(2):258–76. https://doi.org/10.1080/23328940.2015.1043042.

    Article

    Google Scholar

  • 49.

    Richards JR, Lapoint JM, Burillo-Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment. Clin Toxicol. 2018;56(1):15–24. https://doi.org/10.1080/15563650.2017.1349910.

    CAS
    Article

    Google Scholar

  • 50.

    Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci. 2007;25(9):2773–82. https://doi.org/10.1111/j.1460-9568.2007.05521.x.

    CAS
    Article
    PubMed

    Google Scholar

  • 51.

    Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87(2):114–9. https://doi.org/10.1016/j.mayocp.2011.10.005.

    Article
    PubMed
    PubMed Central

    Google Scholar

  • 52.

    Lapoint J, Meyer S, Yu C, Koenig K, Lev R, Thihalolipavan S, et al. Cannabinoid hyperemesis syndrome: public health implications and a novel model treatment guideline. West J Emerg Med. 2018;19(2):380–6. https://doi.org/10.5811/westjem.2017.11.36368.

    Article
    PubMed

    Google Scholar

  • 53.

    • Richards JR, Gordon BK, Danielson AR, Moulin AK. Pharmacologic Treatment of cannabinoid hyperemesis syndrome: a systematic review. Pharmacotherapy. 2017;37(6):725–34. https://doi.org/10.1002/phar.1931 This is a comprehensive review of the evidence behind treatment options in CHS.

    CAS
    Article
    PubMed

    Google Scholar

  • 54.

    Hejazi RA, Reddymasu SC, Namin F, Lavenbarg T, Foran P, McCallum RW. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol. 2010;44(1):18–21. https://doi.org/10.1097/MCG.0b013e3181ac6489.

    Article
    PubMed

    Google Scholar

  • 55.

    Namin F, Patel J, Lin Z, Sarosiek I, Foran P, Esmaeili P, et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil. 2007;19(3):196–202. https://doi.org/10.1111/j.1365-2982.2006.00867.x.

    CAS
    Article
    PubMed

    Google Scholar

  • 56.

    McConachie SM, Caputo RA, Wilhelm SM, Kale-Pradhan PB. Efficacy of capsaicin for the treatment of cannabinoid hyperemesis syndrome: a systematic review. Ann Pharmacother. 2019;53(11):1145–52. https://doi.org/10.1177/1060028019852601.

    CAS
    Article
    PubMed

    Google Scholar

  • 57.

    Wagner S, Hoppe J, Zuckerman M, Schwarz K, McLaughlin J. Efficacy and safety of topical capsaicin for cannabinoid hyperemesis syndrome in the emergency department. Clin Toxicol. 2020;58(6):471–5. https://doi.org/10.1080/15563650.2019.1660783.

    CAS
    Article

    Google Scholar

  • 58.

    Schulze DR, Carroll FI, McMahon LR. Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys. Psychopharmacology. 2012;222(3):425–38. https://doi.org/10.1007/s00213-012-2661-9.

    CAS
    Article
    PubMed
    PubMed Central

    Google Scholar

  • 59.

    Barkin JA, Nemeth Z, Saluja AK, Barkin JS. Cannabis-induced acute pancreatitis: a systematic review. Pancreas. 2017;46(8):1035–8. https://doi.org/10.1097/MPA.0000000000000873.

    Article
    PubMed

    Google Scholar

  • 60.

    Culetto A, Bournet B, Peron J-M, Alric L, Buscail L. Prospective evaluation of the aetiological profile of acute pancreatitis in young adult patients. Pancreatology. 2015;15(3):S66–S7. https://doi.org/10.1016/j.pan.2015.05.252.

    Article

    Google Scholar

  • 61.

    Simons-Linares CR, Barkin JA, Wang Y, Jaiswal P, Trick W, Bartel MJ, et al. Is there an effect of cannabis consumption on acute pancreatitis? Dig Dis Sci. 2018;63(10):2786–91. https://doi.org/10.1007/s10620-018-5169-2.

    Article
    PubMed

    Google Scholar

  • 62.

    Dembiński A, Warzecha Z, Ceranowicz P, Dembiński M, Cieszkowski J, Pawlik WW, et al. Cannabinoids in acute gastric damage and pancreatitis. J Physiol Pharmacol. 2006;57(Suppl 5):137–54.

    PubMed

    Google Scholar

  • 63.

    Kim W, Lao Q, Shin Y-K, Carlson OD, Lee EK, Gorospe M, et al. Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation. Sci Signal. 2012;5(216):ra23. https://doi.org/10.1126/scisignal.2002519.

    CAS
    Article
    PubMed
    PubMed Central

    Google Scholar

  • 64.

    Michler T, Storr M, Kramer J, Ochs S, Malo A, Reu S, et al. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. Am J Physiol Gastrointest Liver Physiol. 2013;304(2):G181–92. https://doi.org/10.1152/ajpgi.00133.2012.

    CAS
    Article
    PubMed

    Google Scholar

  • 65.

    Han B, Gfroerer JC, Colliver JD. Associations between duration of illicit drug use and health conditions: results from the 2005-2007 national surveys on drug use and health. Ann Epidemiol. 2010;20(4):289–97. https://doi.org/10.1016/j.annepidem.2010.01.003.

    Article
    PubMed

    Google Scholar

  • 66.

    Simons-Linares CR, Barkin JA, Jang S, Bhatt A, Lopez R, Stevens T, et al. The impact of cannabis consumption on mortality, morbidity, and cost in acute pancreatitis patients in the United States: a 10-year analysis of the National Inpatient Sample. Pancreas. 2019;48(6):850–5. https://doi.org/10.1097/MPA.0000000000001343.

    Article
    PubMed

    Google Scholar

  • 67.

    Adejumo AC, Akanbi O, Adejumo KL, Bukong TN. Reduced risk of alcohol-induced pancreatitis with cannabis use. Alcohol Clin Exp Res. 2019;43(2):277–86. https://doi.org/10.1111/acer.13929.

    CAS
    Article
    PubMed

    Google Scholar

  • Latest posts